The manufacturers of
reboxetine predict that potent inhibitors of CYP3A4 will reduce its
metabolism. They name
fluvoxamine, but note that
fluvoxamine is more usually considered a potent inhibitor of CYP1A2 and is generally considered a weak inhibitor of CYP3A4.
The manufacturers say that concurrent use of
fluvoxamine should be avoided.